T1	PROC 46 92	Estudio aleatorizado, doble ciego y controlado
T2	PROC 98 118	evaluar la seguridad
#1	AnnotatorNotes T2	C1705187; Safety Study; Research Activity
T3	CHEM 136 159	fármacos experimentales
T4	CHEM 226 236	ribavirina
#2	AnnotatorNotes T4	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	CHEM 238 241	RBV
#3	AnnotatorNotes T5	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T6	DISO 258 306	infección crónica por el virus de la hepatitis C
#4	AnnotatorNotes T6	C0524910; Hepatitis C, Chronic; Disease or Syndrome
T7	PROC 484 530	Estudio aleatorizado, doble ciego y controlado
T8	PROC 536 570	evaluar la eficacia y la seguridad
#5	AnnotatorNotes T8	C0511730; Identify product efficacy and safety issues; Health Care Activity
T9	CHEM 655 665	ribavirina
#6	AnnotatorNotes T9	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T10	CHEM 667 670	RBV
#7	AnnotatorNotes T10	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T11	DISO 687 735	infección crónica por el virus de la hepatitis C
#8	AnnotatorNotes T11	C0524910; Hepatitis C, Chronic; Disease or Syndrome
T12	DISO 818 853	Infección Crónica de la Hepatitis C
T13	PHYS 954 967	posmenopausia
#9	AnnotatorNotes T13	C0206159; Postmenopause; Organism Function
T14	DISO 1012 1021	estériles
#10	AnnotatorNotes T14	C0021359; Infertility; Pathologic Function | C0917730; Female sterility; Finding | C4074771; Sterility, Reproductive; Pathologic Function
T15	PROC 1056 1079	control de la natalidad
#11	AnnotatorNotes T15	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T16	DISO 1080 1099	Hepatitis C Crónica
T17	DISO 1101 1111	infectados
#12	AnnotatorNotes T17	C0009450; Communicable Diseases; Disease or Syndrome | C0439663; Infected; Finding | C3714514; Infection; Pathologic Function
T18	CHEM 1141 1144	ARN
#13	AnnotatorNotes T18	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T19	DISO 1296 1313	cirrósis hepática
T20	PROC 1222 1243	tratamiento antiviral
#14	AnnotatorNotes T20	C2363964; Antiviral treatment; Therapeutic or Preventive Procedure
T21	DISO 1252 1279	infección de la hepatitis C
T22	DISO 1341 1353	Sensibilidad
T23	ANAT 1305 1313	hepática
#15	AnnotatorNotes T23	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T24	CHEM 1380 1387	fármaco
#16	AnnotatorNotes T24	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T25	CHEM 1395 1405	medicación
#17	AnnotatorNotes T25	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T26	PROC 1461 1483	Pruebas de laboratorio
#18	AnnotatorNotes T26	C0022885; Laboratory Procedures; Laboratory Procedure
T27	CHEM 187 194	ABT-450
#19	AnnotatorNotes T27	C3712108; ABT-450; Organic Chemical · Pharmacologic Substance
T28	PROC 1563 1568	HbsAg
#20	AnnotatorNotes T28	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T29	PROC 1572 1634	anticuerpos contra el virus de la inmunodeficiencia humana VIH
#21	AnnotatorNotes T29	C3714540; HIV Antibody Measurement; Laboratory Procedure
T30	CHEM 637 644	ABT-333
#22	AnnotatorNotes T30	C3850285; ABT-333; Organic Chemical · Pharmacologic Substance
T31	DISO 308 311	VHC
#23	AnnotatorNotes T31	C0524910; Hepatitis C, Chronic; Disease or Syndrome
T32	CHEM 626 633	ABT-267
#24	AnnotatorNotes T32	C3713322; ABT-267; Organic Chemical · Pharmacologic Substance
T33	CHEM 1234 1243	antiviral
#25	AnnotatorNotes T33	C0003451; Antiviral Agents; Pharmacologic Substance
T34	PROC 1521 1561	antígeno de superficie de la hepatitis B
#26	AnnotatorNotes T34	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T35	PROC 329 337	tratados
#27	AnnotatorNotes T35	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T36	PROC 1636 1647	Ac anti-VIH
T37	CHEM 160 167	ABT-450
#28	AnnotatorNotes T37	C3712108; ABT-450; Organic Chemical · Pharmacologic Substance
T38	CHEM 197 204	ABT-267
#29	AnnotatorNotes T38	C3713322; ABT-267; Organic Chemical · Pharmacologic Substance
T39	CHEM 178 185	ABT-267
#30	AnnotatorNotes T39	C3713322; ABT-267; Organic Chemical · Pharmacologic Substance
T40	CHEM 208 215	ABT-333
#31	AnnotatorNotes T40	C3850285; ABT-333; Organic Chemical · Pharmacologic Substance
T41	CHEM 168 177	ritonavir
#32	AnnotatorNotes T41	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T42	CHEM 589 596	ABT-450
#33	AnnotatorNotes T42	C3712108; ABT-450; Organic Chemical · Pharmacologic Substance
T43	CHEM 597 606	ritonavir
#34	AnnotatorNotes T43	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T44	CHEM 607 614	ABT-267
#35	AnnotatorNotes T44	C3713322; ABT-267; Organic Chemical · Pharmacologic Substance
T45	CHEM 616 623	ABT-450
#36	AnnotatorNotes T45	C3712108; ABT-450; Organic Chemical · Pharmacologic Substance
T46	PROC 1132 1152	nivel de ARN del VHC
T47	PROC 762 770	tratados
#37	AnnotatorNotes T47	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T48	DISO 737 740	VHC
#38	AnnotatorNotes T48	C0524910; Hepatitis C, Chronic; Disease or Syndrome
T49	Date 13 17	2012
T50	Neg_cue 222 225	sin
T51	LIVB 246 253	adultos
#39	AnnotatorNotes T51	C0001675; Adult; Age Group
T52	Duration 268 275	crónica
#40	AnnotatorNotes T52	C0205191; chronic; Temporal Concept
T53	LIVB 283 306	virus de la hepatitis C
#41	AnnotatorNotes T53	C0220847; hepatitis C virus; Virus
T55	Neg_cue 317 319	no
T57	Neg_cue 651 654	sin
T58	LIVB 675 682	adultos
#42	AnnotatorNotes T58	C0001675; Adult; Age Group
T59	Duration 697 704	crónica
#43	AnnotatorNotes T59	C0205191; chronic; Temporal Concept
T60	LIVB 712 735	virus de la hepatitis C
#44	AnnotatorNotes T60	C0220847; hepatitis C virus; Virus
T62	PROC 746 754	genotipo
#45	AnnotatorNotes T62	C1285573; Genotype determination; Laboratory Procedure
T63	Neg_cue 759 761	no
T64	Duration 828 835	Crónica
#46	AnnotatorNotes T64	C0205191; chronic; Temporal Concept
T65	LIVB 890 897	mujeres
#47	AnnotatorNotes T65	C0043210; Woman; Population Group
T66	Age 898 913	de 18 a 70 años
T67	LIVB 931 938	Mujeres
#48	AnnotatorNotes T67	C0043210; Woman; Population Group
T69	Duration 976 989	más de 2 años
T70	Duration 1092 1099	Crónica
#49	AnnotatorNotes T70	C0205191; chronic; Temporal Concept
T71	PROC 1119 1127	genotipo
#50	AnnotatorNotes T71	C1285573; Genotype determination; Laboratory Procedure
T72	LIVB 1149 1152	VHC
#51	AnnotatorNotes T72	C0220847; hepatitis C virus; Virus
T75	LIVB 1193 1202	Pacientes
#52	AnnotatorNotes T75	C0030705; Patients; Patient or Disabled Group
T76	Neg_cue 1203 1208	nunca
T77	Neg_cue 1280 1282	No
T79	Duration 1431 1444	las 2 semanas
T80	LIVB 1594 1630	virus de la inmunodeficiencia humana
#53	AnnotatorNotes T80	C0019682; HIV; Virus
T81	LIVB 1631 1634	VIH
#54	AnnotatorNotes T81	C0019682; HIV; Virus
T82	LIVB 1644 1647	VIH
#55	AnnotatorNotes T82	C0019682; HIV; Virus
T54	LIVB 880 887	Varones
#56	AnnotatorNotes T54	C0025266; Male population group; Population Group
T56	DISO 1550 1561	hepatitis B
#57	AnnotatorNotes T56	C0019163; Hepatitis B; Disease or Syndrome
A1	Population_data T51 Age
A2	Assertion T4 Negated
A3	Assertion T5 Negated
A4	Assertion T35 Negated
A5	Assertion T9 Negated
A6	Assertion T10 Negated
A7	Population_data T58 Age
A8	Assertion T47 Negated
A9	Assertion T20 Negated
A10	Assertion T19 Negated
A11	Status T35 History_of
A12	Status T22 History_of
A13	Assertion T25 Contraindicated
#58	AnnotatorNotes T1	C0206035; Controlled Clinical Trials, Randomized; Research Activity + C0013072; Double-Blind Method; Research Activity
#59	AnnotatorNotes T3	C0304229; Experimental drug; Pharmacologic Substance
#60	AnnotatorNotes T7	C0206035; Controlled Clinical Trials, Randomized; Research Activity + C0013072; Double-Blind Method; Research Activity
#61	AnnotatorNotes T12	C0524910; Hepatitis C, Chronic; Disease or Syndrome
#62	AnnotatorNotes T21	C0524910; Hepatitis C, Chronic; Disease or Syndrome
#63	AnnotatorNotes T16	C0524910; Hepatitis C, Chronic; Disease or Syndrome
#64	AnnotatorNotes T19	C0023890; Liver Cirrhosis; Disease or Syndrome
#65	AnnotatorNotes T22	C0020517; Hypersensitivity; Pathologic Function
#66	AnnotatorNotes T36	C3714540; HIV Antibody Measurement; Laboratory Procedure
T61	Neg_cue 383 385	no
T68	Quantifier_or_Qualifier 395 404	aprobados
A14	Assertion T68 Negated
#67	AnnotatorNotes T68	C0205540; Approved; Qualitative Concept
T73	Observation 121 127	efecto
#68	AnnotatorNotes T73	C1518681; Outcome of Therapy; Finding (?)
R1	Causes Arg1:T3 Arg2:T73	
R2	Causes Arg1:T37 Arg2:T73	
R3	Causes Arg1:T41 Arg2:T73	
R4	Causes Arg1:T39 Arg2:T73	
R5	Combined_with Arg1:T37 Arg2:T41	
R6	Combined_with Arg1:T41 Arg2:T39	
R8	Combined_with Arg1:T27 Arg2:T38	
R9	Combined_with Arg1:T38 Arg2:T40	
R10	Combined_with Arg1:T39 Arg2:T40	
R7	Combined_with Arg1:T40 Arg2:T4	
R11	Negation Arg1:T50 Arg2:T4	
R12	Combined_with Arg1:T40 Arg2:T5	
R13	Experiences Arg1:T51 Arg2:T73	
R14	Experiences Arg1:T51 Arg2:T3	
R15	Experiences Arg1:T51 Arg2:T37	
R16	Experiences Arg1:T51 Arg2:T6	
R17	Has_Duration_or_Interval Arg1:T6 Arg2:T52	
R18	Causes Arg1:T53 Arg2:T6	
R19	Experiences Arg1:T51 Arg2:T31	
R20	Negation Arg1:T55 Arg2:T35	
R21	Experiences Arg1:T51 Arg2:T35	
R22	Negation Arg1:T61 Arg2:T68	
R23	Combined_with Arg1:T42 Arg2:T43	
R24	Combined_with Arg1:T43 Arg2:T44	
R25	Combined_with Arg1:T45 Arg2:T32	
R26	Combined_with Arg1:T32 Arg2:T30	
R27	Combined_with Arg1:T44 Arg2:T30	
R28	Negation Arg1:T57 Arg2:T9	
R29	Negation Arg1:T50 Arg2:T5	
R30	Negation Arg1:T57 Arg2:T10	
R31	Combined_with Arg1:T30 Arg2:T9	
R32	Combined_with Arg1:T30 Arg2:T10	
R33	Experiences Arg1:T58 Arg2:T42	
R34	Experiences Arg1:T58 Arg2:T11	
R35	Has_Duration_or_Interval Arg1:T11 Arg2:T59	
R36	Causes Arg1:T60 Arg2:T11	
R37	Causes Arg1:T53 Arg2:T31	
R38	Causes Arg1:T60 Arg2:T48	
T74	Quantifier_or_Qualifier 746 757	genotipo 1b
R39	Has_Quantifier_or_Qualifier Arg1:T60 Arg2:T74	
R40	Experiences Arg1:T58 Arg2:T62	
R41	Negation Arg1:T63 Arg2:T47	
R42	Experiences Arg1:T58 Arg2:T47	
R43	Has_Duration_or_Interval Arg1:T12 Arg2:T64	
R44	Has_Age Arg1:T54 Arg2:T66	
R45	Has_Age Arg1:T65 Arg2:T66	
R46	Experiences Arg1:T67 Arg2:T13	
R47	Has_Duration_or_Interval Arg1:T13 Arg2:T69	
T78	PROC 996 1021	quirúrgicamente estériles
#69	AnnotatorNotes T78	C0015787; Female Sterilization; Therapeutic or Preventive Procedure (?)
R48	Experiences Arg1:T67 Arg2:T78	
A15	Status T78 History_of
R49	Experiences Arg1:T67 Arg2:T14	
R50	Experiences Arg1:T67 Arg2:T15	
R51	Has_Duration_or_Interval Arg1:T16 Arg2:T70	
T83	Quantifier_or_Qualifier 1119 1130	genotipo 1b
T84	Result_or_Value 1153 1174	mayor de 10.000 UI/ml
R52	Has_Result_or_Value Arg1:T46 Arg2:T84	
R53	Has_Quantifier_or_Qualifier Arg1:T72 Arg2:T83	
R54	Causes Arg1:T72 Arg2:T16	
R55	Causes Arg1:T72 Arg2:T17	
T85	PROC 1181 1190	selección
#70	AnnotatorNotes T85	C0242802; Patient Selection; Research Activity
R56	Overlap Arg1:T46 Arg2:T85	
R57	Negation Arg1:T76 Arg2:T20	
R58	Negation Arg1:T76 Arg2:T33	
A16	Assertion T33 Negated
R59	Used_for Arg1:T33 Arg2:T20	
R60	Experiences Arg1:T75 Arg2:T21	
R61	Experiences Arg1:T75 Arg2:T20	
R62	Location_of Arg1:T23 Arg2:T19	
R63	Negation Arg1:T77 Arg2:T19	
R64	Causes Arg1:T24 Arg2:T22	
T86	Quantifier_or_Qualifier 1354 1367	significativa
#71	AnnotatorNotes T86	C1546944; Event Seriousness - Significant; Qualitative Concept
R65	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T86	
R66	Overlap Arg1:T25 Arg2:T79	
T87	CONC 1448 1460	dosificación
R67	Has_Duration_or_Interval Arg1:T87 Arg2:T79	
T88	Observation 1461 1493	Pruebas de laboratorio anormales
#72	AnnotatorNotes T88	C3648370; laboratory tests nonspecific abnormal findings; Finding
T89	Result_or_Value 1494 1512	Resultado positivo
#73	AnnotatorNotes T89	C1446409; Positive; Finding
R68	Has_Result_or_Value Arg1:T34 Arg2:T89	
R69	Has_Result_or_Value Arg1:T28 Arg2:T89	
R70	Causes Arg1:T80 Arg2:T89	
R71	Has_Result_or_Value Arg1:T29 Arg2:T89	
R72	Has_Result_or_Value Arg1:T36 Arg2:T89	
R73	Causes Arg1:T81 Arg2:T89	
R74	Causes Arg1:T82 Arg2:T89	
#74	AnnotatorNotes T87	C0178602; Dosage; Quantitative Concept
#75	AnnotatorNotes T46	C4553146; Hepatitis C Virus RNA Measurement; Laboratory Procedure
A17	Experiencer T51 Patient
A18	Experiencer T58 Patient
A19	Experiencer T65 Patient
A20	Experiencer T54 Patient
A21	Experiencer T67 Patient
A22	Experiencer T75 Patient
